PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
Recruiting
Phase 2
Interventional Study
Bladder (Urothelial, Transitional Cell) Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 60 (estimated)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study intends to explore whether the combination of Clostridium butyricum can improve the current situation of poor anti-PD1 treatment effect in patients with bladder cancer.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
For Neoadjuvant therapy:
* T2-T4aN0M0 bladder patients
For Adjuvant therapy:
* Postoperative pathological stage T3-T4 and/or lymph node metastasis were positive.
Exclusion Criteria:
* The researchers evaluated the patients who could not tolerate radical surgery;
* Previousl…
Contacts